Boehringer Ingelheim Signs a Research Agreement with Twist to Discover Therapeutic Antibodies Against Multiple Targets

 Boehringer Ingelheim Signs a Research Agreement with Twist to Discover Therapeutic Antibodies Against Multiple Targets

Boehringer Ingelheim Acquires Abexxa to Expands its Immuno-oncology Research

Shots:

  • Twist to receive an up front for each program and $710M in clinical, regulatory, and commercial milestones for the multiple target discovery programs
  • Boehringer Ingelheim obtains global exclusive rights to develop and commercialize any therapeutic Ab discovered under the collaboration
  • The collaboration will utilize Twist’s Ab libraries that derived from human sequences to discover therapeutic Abs against multiple targets

Click here to read full press release/ article | Ref: | Image: PharmaLive

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post